Technology, Partnerships, Data, and Culture Are Keys to Bringing Precision Medicine to Community Oncology

In January 2025, former FDA Commissioner Stephen Hahn, MD, and fellow panelists at the JP Morgan investors conference observed that pharma no longer follows a path of establishing a presence in one tumor type before moving to the next—today’s news is all about targets, regardless of where cancer emerges.¹